Shardul Amarchand Mangaldas Advised Jusmiral Holdings Limited on ~USD 350 Million (INR 3,093 Crores) ‘On-Market Sale’ of Shares in Cohance Lifesciences Limited
The leading law firm in India, Shardul Amarchand Mangaldas & Co., advised Jusmiral Holdings Limited on an on-market sale of 8.93% shareholding in Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) for approximately USD 350 million (INR 3,093 Crores). Jusmiral Holdings Limited is controlled by funds managed by Advent International.
SAM has previously advised Advent in its control acquisition of Suven Pharmaceuticals Limited through a share purchase and mandatory open offer, as well as on the subsequent merger of Cohance with and into Suven, upon which Suven was renamed Cohance Lifesciences Limited.
The Shardul Amarchand Mangaldas & Co. transaction team was led by Ambarish (Partner), Krishaal Morjaria (Principal Associate), and Varun Natarajan (Senior Associate). The securities law team was led by Kanwardeep Singh Kapany (Counsel), with Ameya Gokhale (Partner) and Kriti Kalyani (Principal Associate) providing additional inputs.
Click to know more about Shardul Amarchand Mangaldas & Co.
If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at [email protected] or call us on +91 8879634922.